Please login to the form below

Not currently logged in
Email:
Password:

Glassia

This page shows the latest Glassia news and features for those working in and with pharma, biotech and healthcare.

Shire receives FDA nod for self-infusion of Glassia

Shire receives FDA nod for self-infusion of Glassia

Shire's emphysema therapy Glassia has received FDA approval for an expanded label, marking the first time that patients can self-infuse at home. ... Glassia, an alpha-1 proteinase inhibitor, is licensed for the treatment of adults with emphysema due to

Latest news

  • Scratching the surface

    UK. Alpha-1 proteinase inhibitor. Glassia (Baxter International)  . Overt hepatic encephalopathy (HE) recurrence.

  • Biologics buoyant

    52 . Kamada/Baxter. Glassia (liquid Alpha-1 Antitrypsin; AAT) – AAT deficiency (US, Canada, Australia and New Zealand)  . FDA approved. 45. Marina Biotech/Cypress Bioscience. Carbetocin (nasal oxytocin analogue)  - autism.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics